Related Experiment Video
Updated: Jul 17, 2026
The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
Published on: April 2, 2014
Lung inflammatory response in pneumonia
1Departament de Medicina, Institut d'Investigations Biomédiques August Pi i Sumyer, Hospital Clínic, Barcelona, Spain.
Abstract:
In normal conditions, alveolar macrophages (AMs) are the main cells that respond to bacteria that reach lower airways. However, if the microbial inoculum is too high or too virulent to be stopped by AM alone, these cells recruit polymorphonuclear neutrophils (PMN) into the alveoli from the vascular compartment. Cytokines, such as tumour necrosis factor-alpha (TNF-alpha), interleukin-1-beta (IL-beta), interleukin-6 (IL-6), and interleukin-8 (IL-8), secreted by the AM are able to attract PMN enhanced for phagocytosis, ready to destroy the invading pathogens. However, excessive cytokine production has deleterious effects, with a systemic inflammatory response (sepsis) that can lead to multiorganic failure and death. Other cytokines, such as interleukin-10 (IL-10) balance this response, attenuating several inflammatory mechanisms. The inflammatory lung response in pneumonia has been well studied in animals, and more recently in humans, using bronchoalveolar lavage to measure some inflammatory mediators (TNF-alpha, IL-1 beta, IL-6, IL-8). From these studies, it seems that: 1) the inflammatory response to pneumonia is compartmentalized for most cytokines (in contrast to adult respiratory distress syndrome (ARDS)), except for IL-6 which is a general marker of inflammation. On the other hand, C-reactive-protein is an acute-phase protein synthesized by the liver through the stimulus of IL-6 that may also be an easy-to-measure marker of inflammation that is directly related to IL-6; 2) some of these cytokines may be useful as prognostic indices; 3) there is no clear relationship between the local lung bacterial burden and the intensity of the inflammatory response; and 4) the administration of granulocyte colony-stimulating factor (G-CSF) is a promising therapeutic approach that is still under clinical investigation. In the future, it is probable that the therapeutic goal in severe pneumonia will be to find the exact point at which inflammation is beneficial but not deleterious. The measurement of the inflammatory response may serve for this purpose.
Insights
Alveolar macrophages initiate pneumonia defense, recruiting neutrophils. Excessive inflammation, marked by cytokines like IL-6, can be harmful, but IL-10 offers balance.
Area of Science:
- Immunology
- Pulmonology
- Critical Care Medicine
Background:
- Alveolar macrophages (AMs) are the primary responders to lower airway bacterial infections.
- Recruitment of polymorphonuclear neutrophils (PMNs) is essential when AMs are overwhelmed, mediated by cytokines like TNF-alpha, IL-1beta, IL-6, and IL-8.
- Excessive inflammation can lead to sepsis and multi-organ failure, while IL-10 helps attenuate these responses.
Purpose of the Study:
- To analyze the inflammatory response in pneumonia, focusing on cytokine profiles and their clinical implications.
- To investigate the compartmentalization of inflammatory mediators in the lung during pneumonia.
- To explore the potential of inflammatory markers as prognostic indices and therapeutic targets.
Main Methods:
- Bronchoalveolar lavage was used to measure inflammatory mediators, including TNF-alpha, IL-1beta, IL-6, and IL-8, in human pneumonia patients.
- C-reactive protein (CRP) levels were assessed as a marker related to IL-6 activity.
- The relationship between bacterial load and inflammatory response intensity was examined.
Main Results:
- Pneumonia's inflammatory response is largely compartmentalized, with IL-6 serving as a general inflammation marker.
- IL-6 correlates with C-reactive protein, a measurable indicator of systemic inflammation.
- Cytokine levels may serve as prognostic indices, though a direct link between bacterial burden and inflammation intensity was not found.
- Granulocyte colony-stimulating factor (G-CSF) shows therapeutic promise but requires further clinical investigation.
Conclusions:
- Understanding pneumonia's inflammatory dynamics, particularly cytokine profiles, is crucial for patient management.
- Targeting the balance between beneficial and deleterious inflammation is a key future therapeutic goal.
- Measuring inflammatory markers can aid in assessing disease severity and guiding treatment strategies.
Related Concept Videos
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:14Atypical Pneumonia
01:29Pneumonia I: Introduction